NASDAQ:AGRX - Agile Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.9552 +0.12 (+14.37 %) (As of 10/21/2018 02:42 AM ET)Previous Close$0.9552Today's Range$0.79 - $0.9752-Week Range$0.23 - $5.33Volume5.51 million shsAverage Volume8.81 million shsMarket Capitalization$28.71 millionP/E Ratio-1.05Dividend YieldN/ABeta1.44 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agile Therapeutics, Inc., a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials. The company is also developing a pipeline of other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey. Receive AGRX News and Ratings via Email Sign-up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:AGRX CUSIPN/A Webwww.agiletherapeutics.com Phone609-683-1880 Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Price-To-Earnings Trailing P/E Ratio-1.05 Forward P/E Ratio-1.59 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.06 per share Price / Book0.90 Profitability EPS (Most Recent Fiscal Year)($0.91) Net Income$-28,300,000.00 Net MarginsN/A Return on Equity-77.24% Return on Assets-55.20% Miscellaneous Employees21 Outstanding Shares34,380,000Market Cap$28.71 million Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions What is Agile Therapeutics' stock symbol? Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX." How were Agile Therapeutics' earnings last quarter? Agile Therapeutics Inc (NASDAQ:AGRX) issued its quarterly earnings data on Friday, August, 3rd. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. View Agile Therapeutics' Earnings History. When is Agile Therapeutics' next earnings date? Agile Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 5th 2018. View Earnings Estimates for Agile Therapeutics. What price target have analysts set for AGRX? 6 brokerages have issued 1-year price objectives for Agile Therapeutics' stock. Their forecasts range from $3.00 to $5.00. On average, they anticipate Agile Therapeutics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 318.8% from the stock's current price. View Analyst Price Targets for Agile Therapeutics. What is the consensus analysts' recommendation for Agile Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agile Therapeutics. What are Wall Street analysts saying about Agile Therapeutics stock? Here are some recent quotes from research analysts about Agile Therapeutics stock: 1. HC Wainwright analysts commented, "it as Just Another Delay; Reiterate Buy but Lower to $8 Stock Data 12/21/2017 Price $4.76 Exchange NASDAQ Price Target $8.00 52-Week High $6.62 52-Week Low $2.04 Enterprise Value (M) $131.3 Market Cap (M) $163 Shares Outstanding (M) 34.2 3 Month Avg Volume 267,948 Short Interest (M) 0.30 Balance Sheet Metrics Cash (M) $43.8 Total Debt (M) $12.1 Total Cash/Share $1.28 EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.27) (0.26)A (0.28) 2Q (0.29) (0.26)A (0.26) 3Q (0.27) (0.22)A (0.29) 4Q (0.18) (0.24) (0.32) FY (1.02) (0.98) (1.16) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 0.0 0.0A 0.0 2Q 0.0 0.0A 0.0 3Q 0.0 0.0A 0.0 4Q 0.0 0.0 0.0 FY 0.0 0.0 0.0 7 6 5 4 3 2 1 DEC- 16 APR- 17 AUG- 17 DEC- 17 20 15 10 5 0 Vol. (mil) Price Twirla Complete Response Letter surprisingly focused on patch adhesion; we believe the issues are readily addressable. The consensus investor Twirla sticking issue has been around the “high” Phase 3 Pearl Index (implied lower efficacy) vs. prior." (12/22/2017) 2. Cantor Fitzgerald analysts commented, "One time when you’re happy to receive a belated Christmas present. The PDUFA date for Twirla is December 26, and we believe it reasonable that an approval will occur around then. We suppose it might be possible that FDA staffers clear their plates before the holiday season. AGRX management has deftly avoided addressing whether labeling discussions have occurred as that would be an indication that FDA approval could be forthcoming." (11/6/2017) Who are some of Agile Therapeutics' key competitors? Some companies that are related to Agile Therapeutics include Provention Bio (PRVB), TapImmune (TPIV), Axsome Therapeutics (AXSM), Aerpio Pharmaceuticals (ARPO), Oncolytics Biotech (ONCYF), Oncomed Pharmaceuticals (OMED), Aridis Pharmaceuticals (ARDS), Northwest Biotherapeutics (NWBO), Vernalis (VNLPY), BioXcel Therapeutics (BTAI), Leap Therapeutics (LPTX), Forward Pharma A/S (FWP), Evofem Biosciences (EVFM), Entasis Therapeutics (ETTX) and Aptevo Therapeutics (APVO). Who are Agile Therapeutics' key executives? Agile Therapeutics' management team includes the folowing people: Mr. Alfred F. Altomari, Chairman & CEO (Age 59)Mr. Scott M. Coiante, CFO & Sr. VP (Age 51)Dr. Elizabeth Ijeoma Onyemelukwe Garner, Sr. VP & Chief Medical Officer (Age 50)Mr. Geoffrey P. Gilmore, Gen. Counsel (Age 52)Mr. Robert G. Conway, Sr. VP of Enterprise Planning & Information Management (Age 61) How do I buy shares of Agile Therapeutics? Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agile Therapeutics' stock price today? One share of AGRX stock can currently be purchased for approximately $0.9552. How big of a company is Agile Therapeutics? Agile Therapeutics has a market capitalization of $28.71 million. The specialty pharmaceutical company earns $-28,300,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Agile Therapeutics employs 21 workers across the globe. What is Agile Therapeutics' official website? The official website for Agile Therapeutics is http://www.agiletherapeutics.com. How can I contact Agile Therapeutics? Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at 609-683-1880 or via email at [email protected] MarketBeat Community Rating for Agile Therapeutics (NASDAQ AGRX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 177 (Vote Underperform)Total Votes: 483MarketBeat's community ratings are surveys of what our community members think about Agile Therapeutics and other stocks. Vote "Outperform" if you believe AGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/21/2018 by MarketBeat.com StaffFeatured Article: What Is An Exchange-Traded Fund (ETF)?